Læknablaðið - 15.11.2011, Qupperneq 15

RANNSÓKN
Heimildir
1. Amórsson T, Torfason B, Ólafsson G, Alfreðsson H,
Jóhannsson KB, Guðbjartsson T. Hjartaskurðlækningar
á íslandi í 20 ár. Ágrip erinda af vísindaþingi Skurð-
læknafélags íslands og Svæfinga- og gjörgæslulæknafélags
íslands. E 24. Læknablaðið 2007; 93: 320.
2. Rajamannan NM, Bonow RO, Rahimtoola SH. Calcific
aortic stenosis: an update. Nat Clin Pract Cardiovasc Med
2007; 4: 254-62.
3. Pai RG, Kapoor N, Bansal RC, Varadarajan P. Malignant
natural history of asymptomatic severe aortic stenosis:
benefit of aortic valve replacement. Ann Thorac Surg 2006;
82: 2116-22.
4. Krane M, Voss B, Hiebinger A, et al. Twenty years of
cardiac surgery in patients aged 80 years and older: risks
and benefits. Ann Thorac Surg 2011; 91: 506-13.
5. Khan SS, Trento A, DeRobertis M, et al. Twenty-year
comparison of tissue and mechanical valve replacement. J
Thorac Cardiovasc Surg 2001; 122: 257-69.
6. Toole JM, Stroud MR, Kratz JM, et al. Twenty-five year
experience with the St. Jude medical mechanical valve
prosthesis. Ann Thorac Surg 2010; 89:1402-9.
7. Emery RW, Krogh CC, Arom KV, et al. The St. Jude Medical
cardiac valve prosthesis: a 25-year experience with single
valve replacement. Ann Thorac Surg 2005; 79: 776-82;
discussion 82-3.
8. Ingvarsdóttir IL, Viktorsson SA, Helgadóttir S, et al.
Lokuskipti vegna ósæðarlokuþrengsla á íslandi 2002-2006:
Ábendingar og snemmkomnir fylgikvillar. Læknablaðið
2011; 97: 523-7.
9. Akins CW, Miller DC, Turina MI, et al. Guidelines for
reporting mortality and morbidity after cardiac valve
interventions. J Thorac Cardiovasc Surg 2008; 135: 732-8.
10. Doty JR, Flores JH, Millar RC, Doty DB. Aortic valve
replacement with medtronic freestyle bioprosthesis:
operative technique and results. J Card Surg 1998; 13: 208-
17.
11. Eichinger WB, Hettich IM, Ruzicka DJ, et al. Twenty-year
experience with the St. Jude medical Biocor bioprosthesis
in the aortic position. Ann Thorac Surg 2008; 86:1204-10.
12. David TE, Ivanov J, Armstrong S, Feindel CM, Cohen G.
Late results of heart valve replacement with the Hancock II
bioprosthesis. J Thorac Cardiovasc Surg 2001; 121: 268-77.
13. Vrandecic M, Fantini FA, Filho BG, de O, da C, Vrandecic
E. Long-term results with the Biocor-SJM stentless porcine
aortic bioprosthesis. J Heart Valve Dis 2002; 11:47-53.
14. Polvani G, Barili F, Dainese L, et al. Long-term results
after aortic valve replacement with the Bravo 400 stentless
xenograft. Ann Thorac Surg 2005; 80:495-501.
15. Ali A, Lim E, Halstead J, et al. Porcine or human stentless
valves for aortic valve replacement? Results of a 10-year
comparative study. J Heart Valve Dis 2003; 12: 430-5;
discussion 435.
16. Auriemma S, D'Onofrio A, Brunelli M, et al. Long-term
results of aortic valve replacement with Edwards Prima
Plus stentless bioprosthesis: eleven years' follow up. J
Heart Valve Dis 2006; 15:6 91-5; discussion 695.
17. Bonow RO, Carabello BA, Chatterjee K, et al. 2008
focused update incorporated into the ACC/AHA 2006
guidelines for the management of patients with valvular
heart disease: a report of the American College of
Cardiology/American Heart Association Task Force on
Practice Guidelines (Writing Committee to revise the 1998
guidelines for the management of patients with valvular
heart disease). Endorsed by the Society of Cardiovascular
Anesthesiologists, Society for Cardiovascular Angio-
graphy and Interventions, and Society of Thoracic Surge-
ons. J Am Coll Cardiol 2008; 52: el-142.
18. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic
and bleeding complications in patients with mechanical
heart valve prostheses. Circulation 1994; 89: 635-41.
19. Horstkotte D, Schulte H, Bircks W, Strauer B. Unexpected
findings conceming thromboembolic complications and
anticoagulation after complete 10 year follow up of
patients with St. Jude Medical prostheses. J Heart Valve
Dis 1993; 2: 291-301.
20. Koertke H, Minami K, Boethig D, et al. INR self-
management permits lower anticoagulation levels after
mechanical heart valve replacement. Circulation 2003; 108
Suppl 1: II75-8.
21. Sjogren J, Gudbjartsson T, Thulin LI. Long-term outcome
of the MitroFlow pericardial bioprosthesis in the elderly
after aortic valve replacement. J Heart Valve Dis 2006; 15:
197-202.
22. Butchart EG, Li HH, Payne N, Buchan K, Grunkemeier GL.
Twenty years' experience with the Medtronic Hall valve. J
Thorac Cardiovasc Surg 2001; 121:1090-100.
23. Bach DS, Kon ND, Dumesnil JG, Sintek CF, Doty DB.
Ten-year outcome after aortic valve replacement with the
freestyle stentless bioprosthesis. Ann Thorac Surg 2005; 80:
480-6; discussion 486-7.
ENGLISH SUMMARY
Aortic valve replacement for aortic stenosis in lceland 2002-2006: Long term complications and survival
Viktorsson SA , Ingvarsdottir IL, Hreinsson K, Sigurdsson Ml, Helgadottir S, Arnorsson Th, Danielsen R, Gudbjartsson T
Objective: To investigate long-term complications and survival following aortic valve replacement (AVR) in patients with aortic stenosis (AS) in lceiand.
Material and methods: Included were 156 patients (average age 71.7 yrs, 64.7% males) that underwent AVR for AS at Landspitali between 2002 and
2006. A mechanical prosthesis was used in 29 patients (18.6%) and a bioprosthesis in 127. Long-term complications and operation-related admissions
were registered from hospital and outpatient records until April 1,2010. Overall survival was estimated and compared with the icelandic population of the
same age and gender.
Results: The mean preop. EuroSCORE(st) was 6.9%, the max. transvalvular pressure gradient 74.1 mmHg and the left ventricular ejection fraction (LVEF)
(57.2%). At six months following AVR the maximal pressure gradient was 19.8 mmHg (range; 2.5-38). Echocardiography results were not available for
23.6% of the patients 6 months postoperatively. In the follow-up period one in four patients was admitted due to valve-related problems. Re-admission
rate was 6.0/100 patient-years (pt-y); most commonly due to cardiac failure (1.7/100 pt-y), emboli (1.6/100 pt-y), hemorrhage (1.6/100 pt-y), endocarditis
(0.7/100 pt-y) and myocardial infarction (0.4/100 pt-y). Survival at 1 and 5 year was 89.7% and 78.2%, respectively, making survival comparable to the
estimated survival of lcelanders of the same age and gender.
Conclusions: The rate of long-term complications following AVR in lceland is in line with other studies. The same applies to long-term survival, which was
similar to that of the lcelandic population of the same age and gender.
Key words: Aortic valve replacement, aortic stenosis, heart surgery, results, iong-term complication, survival.
Correspondence: Tómas Guðbjartsson, tomasgud<dlandspitali.is
LÆKNAblaðið 2011/97 595